Polymersomes for Sustained Delivery of a Chalcone Derivative Targeting Glioblastoma Cells

• Tipo: Artigo em Revista Científica Internacional
• Data: 2024

Autores

Alves, A (Autor) Outra; Silva, AM (Autor) Outra; Moreira, J (Autor) Outra; Nunes, C (Autor) Outra; Salette Reis (Autor) FFUP; Pinto, M (Autor) Outra; Honorina Cidade (Autor) FFUP; Rodrigues, F (Autor) Outra; Ferreira, D (Autor) Outra; Paulo Costa (Autor) FFUP; Marta Correia da Silva (Autor) FFUP

Revista

Título: Brain Sciences

Vol. 14 Nº Article 907

Página Final: 82

ISSN: 2076-3425

Editora: MDPI

Indexação

ISI Web of Knowledge - 2 Citações

Scopus - 2 Citações

Outras Informações

ID Authenticus: P-00Z-V4F

DOI: 10.3390/brainsci14010082

Abstract (EN): Glioblastoma (GBM) is a primary malignant tumor of the central nervous system responsible for the most deaths among patients with primary brain tumors. Current therapies for GBM are not effective, with the average survival of GBM patients after diagnosis being limited to a few months. Chemotherapy is difficult in this case due to the heterogeneity of GBM and the high efficacy of the blood-brain barrier, which makes drug absorption into the brain extremely difficult. In a previous study, 3 ',4 ',3,4,5-trimethoxychalcone (MB) showed antiproliferative and anti-invasion activities toward GBM cells. Polymersomes (PMs) are an attractive, new type of nanoparticle for drug administration, due to their high stability, enhanced circulation time, biodegradability, and sustained drug release. In the present study, different MB formulations, PEG2000-PCL and PEG5000-PCL, were synthesized, characterized, and compared in terms of 14-day stability and in vitro cytotoxicity (hCMEC/D3 and U-373 MG).

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 14